Tirapazamine

Tirapazamine

Skeletal formula
Space-filling model
Systematic (IUPAC) name
4-hydroxy-1-oxido-1,2,4-benzotriazin-1-ium-3-imine
Identifiers
CAS Number	27314-97-2 Y
ATC code	none
PubChem	CID: 33776
ChemSpider	10437748 N
UNII	1UD32YR59G N
KEGG	D06167 Y
ChEBI	CHEBI:78887 N
ChEMBL	CHEMBL50882 N
Chemical data
Formula	C7H6N4O2
Molecular mass	178.148 g/mol
SMILES C1=CC=C2C(=C1)N(C(=N)N=[N+]2[O-])O
InChI InChI=1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9) N Key:ORYDPOVDJJZGHQ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Tirapazamine (SR-4233) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective. As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types.

Chemically it is an aromatic heterocycle di-N-oxide. Its full chemical name is 3-amino-1,2,4-benzotriazine-1,4 dioxide. Originally it was prepared in a programme screening for new herbicides in 1972. Its clinical use was first described by Zeman et al. in 1986. While tirapazamine has had only limited effectiveness in clinical trials, it has been used as a lead compound to develop a number of newer compounds with improved anti-cancer properties.

An update of a Phase III trial (Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group) found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improved overall survival.

Two possible molecular mechanisms of TPZ, for generating reactive oxygen species which causes DNA strand break, have been considered widely. In hypoxia, under bioreductive condition, it has been observed that TPZ primarily produces hydroxyl or and benzotriazinyl radicals as the DNA damaging reactive species.

A new clinical phase I trial of Tirapazamine combined with embolization in liver cancer has been received in June, 2014. This study will help to optimize the safe tollerable dose of TPZ, when it is administered with embolization in liver cancer. Treatment of solid tumors is compliated by the fact that these are often poorly provided with blood vessels, thus limiting their exposure to cytotoxic agents. Attempts have, however, been made to take advantage of the resulting hypoxic environment by designing drugs that are nonreactive until they are reduced to reactive species in oxygen-deficient tissues. This, it is hoped, will lead to enhanced selectivity. The azaquinoxaline dioxide function on the antineoplastic agent tirapazamine, for example, has been shown to give reactive nitroxide radicals on reduction.

Synthesis

File:Tirapazamine synthesis.svg

Tirapazamine synthesis:

The first step in the synthesis, condensation of 2-nitroaniline (1) with cyanamide, probably involves initial formation of a guanidine such as 2. This then cyclizes to the heterocycle 3. Oxidation with hydrogen peroxide then completes the preparation of tirapazamine (4).

External links

• Clinical trial number NCT00033410 for "Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer" at ClinicalTrials.gov